next generation in-vivo cell AND GENE THERAPies
Interius Biotherapeutics is at the nexus of gene and cell therapy. Using next-generation lentiviral pseudotyping, we aim to enable the efficiency and specificity required for direct patient administration of gene therapies.
Interius aspires to transform cell and gene therapy through in-vivo generation of therapeutic immune and blood cells including:
• Chimeric Antigen Receptor T Cells (CAR-T) for cancers,
• Regulatory T Cells (Treg) for autoimmune diseases, and
• CD34+ Hematopoietic Stem Cells (HSC) for blood disorders
This “off-the-shelf” approach overcomes the time and expense associated with ex-vivo manufacturing for existing cell and gene therapies. Further application of our technology circumvents the toxicities of required myeloablative regimens.
Interius was co-founded by Saar Gill, M.D., Ph.D., Scientific co-director, Transplant & Cell Therapy program at The University of Pennsylvania, and a foremost inventor in the CAR-T field and Bruce Peacock, an experienced biotechnology executive and successful entrepreneur.